Insurance and Scheme Coverage for CAR-T by Product

Sometimes, partly, and never automatically. No Indian regulation names CAR-T as a treatment insurers must cover. Some policies exclude cell and gene therapy outright. Some allow it as a hospitalisation with written pre-authorisation. Almost all are capped by a sum insured far below the cost of a single course.

Three separate questions decide the answer, and they are settled in this order.

1. Does the wording exclude it? IRDAI's 2019 guidelines on standardisation of exclusions require indemnity policies to cover a defined list of modern treatment methods. That list names oral chemotherapy, immunotherapy given as a monoclonal antibody injection, and haematopoietic stem-cell therapy for bone-marrow transplant. CAR-T cell therapy is not a named entry on it. The automatic protection a monoclonal antibody infusion enjoys therefore does not extend to a CAR-T infusion.
2. Is the treatment inside an approved indication? Many refusals rest on an unproven or experimental treatment clause. That clause reads very differently now that two CD19-directed CAR-T products hold CDSCO marketing approval in India for defined indications. Where the patient is being treated inside the approved indication, say so explicitly in the pre-authorisation and attach the approval evidence rather than leaving a reviewer to assume.
3. Is the sum insured large enough? This is where most families stop. With published figures for the therapy alone sitting in the tens of lakhs, before the admission, the lymphodepleting chemotherapy and the management of cytokine release syndrome are added, a ₹5 lakh or ₹10 lakh policy cannot fund a course even when nothing in the wording excludes it.

Business reporting has been blunt about the practice. Mint reported on 14 November 2024 that insurers typically do not cover gene therapy, CAR-T cell therapy or proton-beam therapy. That is a description of what commonly happens, not a rule, and individual policies do differ.

The practical conclusion is uncomfortable but useful. Insurance is better treated as one contribution among several than as the plan. Families who complete CAR-T in India almost always assemble the money from a policy, a manufacturer financing programme, a relief fund and their own resources at the same time, because no single route reaches the total.

Nothing here is a reading of your policy. Only your insurer, in writing, against your policy number and your diagnosis, can tell you what is covered.

Mostly through price and approval status, not through policy wording. A policy that excludes cell and gene therapy excludes every product equally. Where it does not exclude them, what differs sharply is the size of the gap a family must fund itself, and which published manufacturer programme exists to help close it.

Figures above are indicative published amounts, as of August 2026, attributed to the sources named in each cell. They are not a CION price list and not a quote, and CION does not supply CAR-T or any cell therapy. Only the authorised centre's written estimate is your number.

Partly, and never enough on its own. No central scheme currently funds a full CAR-T course. Ayushman Bharat PM-JAY covers up to ₹5 lakh per eligible family per year and has no dedicated CAR-T package. Rashtriya Arogya Nidhi and state relief funds can contribute, at government institutions, for families who qualify.

These are the routes that actually exist, and what each one can and cannot do.

• Ayushman Bharat PM-JAY. Up to ₹5 lakh per eligible family per year, cashless at empanelled hospitals. The Press Information Bureau describes the cancer benefit as covering chemotherapy, radiotherapy and surgical oncology. It is not a CAR-T package and cannot fund a course, but it can absorb parts of an admission and supportive care at an empanelled hospital.
• Rashtriya Arogya Nidhi and the Health Minister's Cancer Patient Fund. Assistance for patients living below the poverty line, for treatment at government super-speciality hospitals and regional cancer centres, with support described up to ₹15 lakh per patient. Applications are routed through the treating government institution rather than made directly, and the paperwork takes time.
• Health Minister's Discretionary Grant, the Prime Minister's National Relief Fund and Chief Minister's Relief Funds. Discretionary, decided case by case, with no entitlement and no fixed amount. Worth applying to in parallel rather than in sequence, because each has its own queue.
• State schemes, including Aarogyasri in Telangana and Andhra Pradesh. These work through a published package list with a ceiling against each package. No CAR-T package is published, so the realistic use is for parts of the surrounding admission and supportive care. Package lists and ceilings are revised, so the hospital's scheme desk is the only current source. Indicative, as of August 2026.
• Employer cover, CGHS, ECHS and ESIC. Rules differ from retail insurance and each has its own referral and prior-approval route. That process is started on the day CAR-T is first discussed, because approvals move slowly and the manufacturing clock does not.

Scheme ceilings and package lists are stated here in text only and are indicative, as of August 2026. Confirm the current figure with the hospital's scheme desk before relying on it.

Paying for it and being eligible for it are two different questions, and eligibility is the harder one. A coverage page is exactly where hope tends to outrun eligibility, so this belongs here rather than in a footnote. The overwhelming majority of people with cancer in India are not candidates for CAR-T at any price, and no funding route changes that.

CAR-T is generally not an option, or is considered only with specialist caution, for people who:

• have a cancer that is not a B-cell lymphoma or B-cell acute lymphoblastic leukaemia — solid tumours sit outside the approved Indian indications entirely, and this is by far the largest group;
• have a B-cell cancer whose cells do not carry CD19 on testing, since that is the target both Indian products are built around;
• have not yet had, or have not exhausted, the standard lines of treatment that come before cell therapy in the pathway;
• fall outside the approved age or indication range for the specific product — Qartemi's Indian approval is for adults aged 18 and above with relapsed or refractory B-cell non-Hodgkin lymphoma, and the centre will confirm which product applies;
• are not well enough overall, or whose heart, lung, liver or kidney function will not tolerate lymphodepleting chemotherapy and the possibility of cytokine release syndrome;
• have an active, uncontrolled infection at the time of the planned treatment;
• are pregnant or breastfeeding, where safety data is not available;
• cannot arrange a caregiver and accommodation near an authorised centre for the weeks required after the infusion, which is a safety requirement rather than a convenience.

None of these are rules you can apply to yourself from a web page, and none of them are reasons to rule yourself out before a specialist has looked. They are the reasons a haematologist may decline CAR-T even when the money has been found. Only the treating team at an authorised centre, with your pathology, CD19 status, treatment history and current fitness in front of them, can answer whether any of it applies to you.

More than a hospital bill, and most of it before treatment starts. A CAR-T pre-authorisation stands or falls on documents that prove the diagnosis, the CD19 target, the failure of earlier lines, the approved indication and the centre's authorisation. Assemble them before leukapheresis. Afterwards, the cost is already committed.

Eligibility first, money second, and both before cell collection. Manufacturing starts a clock and a cost. Every question that is easy to ask in week one becomes expensive to ask in week six. This is the order experienced financial counsellors at CAR-T centres work in.

1. Confirm eligibility at an authorised centre. Diagnosis, CD19 status and prior lines assessed by the haematology team. Until this is settled, the coverage question is premature.
2. Obtain an itemised written estimate. Product on its own line, everything around it on theirs, so that each funding route can be pointed at the lines it is capable of paying.
3. Send the pre-authorisation with the full file. Clinical justification, pathology, CD19 report, prior treatment records and the approval evidence, in one submission rather than in instalments.
4. Ask for the insurer's decision in writing. The amount approved, the clause applied, and any sub-limit. If it is a refusal, ask which clause it rests on, since that is what an appeal or an Ombudsman complaint is built from.
5. Open the manufacturer's financing application in parallel. Both Indian manufacturers have published programmes, both are assessed by the financing partner rather than by the hospital, and both take time.
6. File the scheme and relief-fund applications at the same time. Rashtriya Arogya Nidhi, state relief funds and hospital trust support each have their own queue. Filing them in sequence wastes the weeks you have.
7. Agree the plan if the money falls short mid-pathway. An uncomfortable conversation that belongs in week one, and one every experienced counsellor expects a family to raise.

Anyone quoting a firm all-in CAR-T figure without seeing your reports, or promising that a claim will be settled, is not describing how this works. Sourced ranges and a centre's written estimate are the only numbers worth planning around.

CION Cancer Clinics does not provide CAR-T or any other cell therapy, and does not stock, administer or price any CAR-T product. CAR-T in India is delivered at authorised centres with apheresis facilities, cell-manufacturing logistics and the intensive monitoring the treatment requires. A referral to one of those centres is made by your treating haematologist.

What CION centres do provide is day-care immunotherapy and chemotherapy where that is the plan a treating team has arrived at, and orientation material like this page for families trying to understand a pathway before they walk into it. Those are different things, and the difference matters legally as well as practically.

If you are working through the CAR-T question, the companion pages in this section carry the parts this one does not. Applying for CAR-T: The Referral Pathway Step by Step sets out how a referral is actually made and what the centre will ask for. Qartemi: India's Second Approved CAR-T Therapy covers the product, its approved indication and its regulatory history, and Qartemi Cost and Access takes the published cost reporting and the access route in detail. For the wider set of molecule guides, comparisons and cost pages, start from Immunotherapy Medicines Explained, and for how immunotherapy as a whole is used in Indian practice, see the immunotherapy overview.